T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances

T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances

T-cell specificity can be redirected against tumor antigens either ex vivo using engineered chimeric antigen receptor (CAR) T-cells or in vivo by bridging natural T-cells and tumor cells with bispecific T-cell engager (TCE) antibodies. Currently, four CAR T-cells have been approved by the FDA for th...

Full description

Bibliographic Details
Main Authors: Ondine Messéant, Roch Houot, Guillaume Manson
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
lymphoma
immunotherapy
CAR T-cells
bispecific antibody
T-cells engager
Online Access:https://www.mdpi.com/2072-6694/13/17/4274
id doaj-30b3b0db22674df4844e16c30d91660f
record_format Article
spelling doaj-30b3b0db22674df4844e16c30d91660f2021-09-09T13:40:14ZengMDPI AGCancers2072-66942021-08-01134274427410.3390/cancers13174274T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent AdvancesOndine Messéant0Roch Houot1Guillaume Manson2Department of Hematology, University Hospital of Rennes, 35000 Rennes, FranceDepartment of Hematology, University Hospital of Rennes, 35000 Rennes, FranceDepartment of Hematology, University Hospital of Rennes, 35000 Rennes, FranceT-cell specificity can be redirected against tumor antigens either ex vivo using engineered chimeric antigen receptor (CAR) T-cells or in vivo by bridging natural T-cells and tumor cells with bispecific T-cell engager (TCE) antibodies. Currently, four CAR T-cells have been approved by the FDA for the treatment of B-cell lymphomas, including diffuse large B cell lymphomas (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). No TCE have yet been approved for the treatment of B-cell lymphomas. However, at least four of them are in clinical development and show promising activity. Here, we review the most recent advances of CAR T-cells and TCE in the treatment of B-cell lymphomas.https://www.mdpi.com/2072-6694/13/17/4274lymphomaimmunotherapyCAR T-cellsbispecific antibodyT-cells engager
collection DOAJ
language English
format Article
sources DOAJ
author Ondine Messéant
Roch Houot
Guillaume Manson
spellingShingle Ondine Messéant
Roch Houot
Guillaume Manson
T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
Cancers
lymphoma
immunotherapy
CAR T-cells
bispecific antibody
T-cells engager
author_facet Ondine Messéant
Roch Houot
Guillaume Manson
author_sort Ondine Messéant
title T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
title_short T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
title_full T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
title_fullStr T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
title_full_unstemmed T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
title_sort t-cell redirecting therapies for the treatment of b-cell lymphomas: recent advances
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-08-01
description T-cell specificity can be redirected against tumor antigens either ex vivo using engineered chimeric antigen receptor (CAR) T-cells or in vivo by bridging natural T-cells and tumor cells with bispecific T-cell engager (TCE) antibodies. Currently, four CAR T-cells have been approved by the FDA for the treatment of B-cell lymphomas, including diffuse large B cell lymphomas (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). No TCE have yet been approved for the treatment of B-cell lymphomas. However, at least four of them are in clinical development and show promising activity. Here, we review the most recent advances of CAR T-cells and TCE in the treatment of B-cell lymphomas.
topic lymphoma
immunotherapy
CAR T-cells
bispecific antibody
T-cells engager
url https://www.mdpi.com/2072-6694/13/17/4274
work_keys_str_mv AT ondinemesseant tcellredirectingtherapiesforthetreatmentofbcelllymphomasrecentadvances
AT rochhouot tcellredirectingtherapiesforthetreatmentofbcelllymphomasrecentadvances
AT guillaumemanson tcellredirectingtherapiesforthetreatmentofbcelllymphomasrecentadvances
_version_ 1717760713713254400

Similar Items